Brief: Ribomic Announces Preliminary Topline Data From Phase 2 Trials Of Rbm-007 Eye Disorder Drug

Ribomic

28/12/2021 14:30

Dec 28 (Reuters) - Ribomic Inc  4591.T :
    * RIBOMIC ANNOUNCES PRELIMINARY TOPLINE DATA FROM PHASE 2
TRIALS
OF RBM-007 FOR WET AGE-RELATED MACULAR DEGENERATION
    * RIBOMIC INC - RBM-007 MONOTHERAPY OR RBM-007 IN
COMBINATION WITH
EYLEA DID NOT DEMONSTRATE VISION IMPROVEMENT OVER
EYLEAMONOTHERAPY
    * RIBOMIC - IN TREATMENT NAÏVE WAMD PATIENTS, PRELIM INTERIM
DATA
FROM PHASE 2 TEMPURA TRIAL ARE SHOWING IMPROVEMENT IN VISION AND
RETINAL ANATOMY
    * RIBOMIC INC - ADDITIONAL ANALYSES OF SECONDARY ENDPOINTS
OF TOFU
ARE ONGOING

Source text for Eikon:  ID:nBw77ccKLa 
Further company coverage:  4591.T 

 ((Reuters.Briefs@thomsonreuters.com;))